NeoGenomics, Inc. (NEO)
Market Cap | 1.57B |
Revenue (ttm) | 551.62M |
Net Income (ttm) | -114.67M |
Shares Out | 127.55M |
EPS (ttm) | -0.92 |
PE Ratio | n/a |
Forward PE | 222.22 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,478,838 |
Open | 12.67 |
Previous Close | 12.51 |
Day's Range | 11.90 - 12.68 |
52-Week Range | 6.00 - 20.54 |
Beta | 1.08 |
Analysts | Buy |
Price Target | 19.33 (+57.15%) |
Earnings Date | Nov 7, 2023 |
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence ... [Read more]
Financial Performance
In 2022, NeoGenomics's revenue was $509.73 million, an increase of 5.24% compared to the previous year's $484.33 million. Losses were -$144.25 million, 1628.2% more than in 2021.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for NEO stock is "Buy." The 12-month stock price forecast is $19.33, which is an increase of 57.15% from the latest price.
News

NeoGenomics Reports Second Quarter 2023 Results
Second Quarter Revenue Increased 18% to $147 Million FORT MYERS, FL / ACCESSWIRE / August 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today a...

NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
FT. MYERS, FL / ACCESSWIRE / July 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today that the Molecular Diagnostics Services Program (MolDx) has co...

NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
FT. MYERS, FL / ACCESSWIRE / July 18, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that it will report its secon...

Press release Biocartis Group NV: Biocartis appoints George Cardoza as new CFO and Head of Service Delivery
PRESS RELEASE - INSIDE INFORMATION/ REGULATED INFORMATION 18 July 202 3 , 7:00 AM CE S T

NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth ...

NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
FT. MYERS, FL / ACCESSWIRE / June 15, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that its RaDaR® assay, a pers...

NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
FT. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaD...

NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
FT MYERS, FL / ACCESSWIRE / June 1, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...

NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO
FT. MYERS, FL / ACCESSWIRE / May 30, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data supporting its cancer...

NeoGenomics Reports First Quarter 2023 Results
First Quarter Revenue Increased 17% to $137 Million FORT MYERS, FL / ACCESSWIRE / May 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing se...

NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference
FT. MYERS, FL / ACCESSWIRE / May 3, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...

NeoGenomics to Announce First Quarter 2023 Financial Results
FT. MYERS, FL / ACCESSWIRE / April 17, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that it will release its fir...

NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare Conference
FT. MYERS, FL / ACCESSWIRE / April 11, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announ...

NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023
FT. MYERS, FL / ACCESSWIRE / April 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the company and its coll...

NeoGenomics to Host Investor Day on April 4, 2023
FT. MYERS, FL / ACCESSWIRE / March 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the Company will host a...

Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care
FT. MYERS, Fla. & NEW YORK--(BUSINESS WIRE)-- #AI--Massive Bio, Inc., a private AI-enabled oncology startup that provides virtual and in-person concierge services for cancer patients, and NeoGenomics,...

NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test
FT MYERS, FL / ACCESSWIRE / March 16, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the commercial availability o...

NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP
FT. MYERS, FL / ACCESSWIRE / March 13, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the expansion of their next-...

NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference
FT. MYERS, FL / ACCESSWIRE / February 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today ann...

NeoGenomics Reports Fourth Quarter and Full Year 2022 Results
Fourth Quarter Revenue Increased 10% to $139 million; Full Year Revenue Increased 5% to $510 million FORT MYERS, FL / ACCESSWIRE / February 23, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company") , ...

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of NeoGenomics Laboratories, Inc. (NEO) Investigation
NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeoGenomics Laboratories, Inc. ("NeoGenomics" or "the ...

NEO IMPORTANT DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages NeoGenomics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 6 Deadline in Securities Class Action - NEO
NEW YORK , Feb. 7, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NeoGenomics, Inc. (NASDAQ: NEO) between February 27, 2020 and Ap...

NeoGenomics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 6, 2023 to Discuss Your Rights - NEO
New York, New York--(Newsfile Corp. - February 6, 2023) - Levi & Korsinsky, LLP notifies investors in NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO) of a class action securities laws...

RaDaR(R) Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery
Newly-published data shows a strong link between tumor DNA circulating in blood and patient responses to investigational neoadjuvant treatment with immune therapies FT. MYERS, FL / ACCESSWIRE / Februa...

NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023
FT. MYERS, FL / ACCESSWIRE / February 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that it plans to release i...